Presented by VT School of Neuroscience
Eric J. Nestler, M.D., Ph.D.
“Transcriptional and Epigenetic Mechanisms of Depression”
- 7:30 PM March 19, 2018
- Holtzman Alumni Center Assembly Hall
- Public reception from 6pm – 7pm
Depression is a common, chronic, and debilitating syndrome. Although many patients benefit from antidepressant medications or other therapies, only about half of depressed patients show a complete remission, which underscores the need for more effective agents. The mechanisms that precipitate depression, such as stress, are incompletely understood. One mystery of the disease is its long-lasting nature and delayed response to antidepressant treatment. This persistence is thought to be mediated by slowly developing but stable adaptations in the brain, which might include regulation of gene expression and chromatin structure.
We have used chronic social defeat stress as an animal model of depression that mimics certain symptoms of human depression. Prolonged exposure to an aggressor induces lasting changes in mouse behavior such as social avoidance, which are reversed by chronic (but not acute) treatment with available antidepressants. Importantly, roughly one-third of mice subjected to social defeat stress do not exhibit these deleterious behaviors and appear “resilient.” We are exploring the molecular basis of defeat-induced behavioral pathology, antidepressant action, and resilience by analyzing genome-wide changes in gene expression and chromatin modifications. Our work to date has focused on the nucleus accumbens, a key brain reward region implicated in aspects of depression. as well as several other limbic brain regions. Parallel work has focused on homologous regions in the brains of depressed humans examined postmortem.
Together, this work is providing novel insight into the molecular mechanisms underlying depression and other stress-related disorders. The findings also suggest novel leads for the development of new antidepressant treatments. For example, our findings on resilience suggest the novel approach of developing medications that promote resilience and not just those that oppose the deleterious effects of stress.